| Serial Number | 88372290 |
| Word Mark | QUELL |
| Filing Date | Thursday, April 4, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 16, 2020 |
| Registration Number | 6077717 |
| Registration Date | Tuesday, June 16, 2020 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 31, 2020 |
| Goods and Services | Manufacturing and processing pharmaceuticals for others; manufacturing and processing biological, biotechnological and biopharmaceutical preparations for others; processing of biological tissue, blood, cell, and genetic material for others; production and manufacture of viral vectors for others; production and manufacture of gene therapy products for others; custom manufacture of pharmaceutical and biological preparations for others; none of the foregoing having any relation to pain treatment or management |
| Goods and Services | Pharmaceutical and biological preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; veterinary preparations for diagnostic, medical, therapeutic, and prophylactic use for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for cell therapy, namely, preparations comprising T cells having an immunosuppressive phenotype; preparations for gene therapy; pharmaceutical, medical, and clinical preparations for use in treatment, amelioration and prophylaxis of immune system related diseases and disorders; preparations for therapies to modulate the immune system for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapies for autoimmune conditions and immunological disorders; cancer preparations, namely, chimeric antigen receptors and therapeutic preparations thereof for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; diagnostic kits consisting of monoclonal antibodies for use in disease testing and for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for therapeutic delivery of nucleic acids for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; viral or nucleic acid vectors for therapeutic or prophylactic purposes and preparations containing such vectors for inducing tolerance to a transplant and for treating, preventing or ameliorating transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; preparations for genetically modifying human and animal cells for diagnostic and medical purposes; preparations of blood or cells extracted from humans or animals which have been adapted for therapeutic purposes; none of the foregoing having any relation to pain treatment or management |
| Goods and Services | Medical services; medical services in the field of immunology; medical services in the field of surgery; medical services in the field of autoimmune diseases and conditions; medical services, in the field of, tissue transplant surgery; collection and preservation of biological tissue, blood, cells and genetic materials; medical diagnosis of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; Medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; providing information and data for diagnosis and medical treatment of transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; gene and nucleic acid delivery or modification for therapeutic purposes; medical treatment, namely, administering cell or gene therapies; advisory services in the field of health as it relates to cell or gene therapy; medical advisory services relating to cell or gene therapy; none of the foregoing having any relation to pain treatment or management |
| Goods and Services | advisory services relating to gene therapy and design; Scientific and technological services, namely, research and design in the field of T cells with an immunosuppressive phenotype and transplant rejection, Graft-versus-Host Disease (GvHD), autoimmune and allergic disease, undesired inflammation and inflammatory disease, and for promoting tissue repair and regeneration; industrial analysis and research in the field of cell therapy; medical and veterinary research services in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new therapies in the field of autoimmune, immunological disorders and to modulate the immune system; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; scientific and technological services, namely, design in the field of cell therapy; none of the foregoing having any relation to pain treatment or management |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 22, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 22, 2019 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 22, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, April 22, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Quell Therapeutics Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | London W120BZ GB |
| Party Name | Quell Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | London WC1B3SR GB |
| Party Name | Quell Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | London WC1B3SR GB |
| Event Date | Event Description |
| Wednesday, January 25, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, January 25, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, January 25, 2023 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Wednesday, January 25, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, January 25, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, January 25, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, June 16, 2020 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, March 31, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 31, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, March 11, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 25, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 25, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, February 25, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, February 25, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, February 25, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, February 13, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 13, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 13, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, January 23, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, January 23, 2020 | NON-FINAL ACTION E-MAILED |
| Thursday, January 23, 2020 | NON-FINAL ACTION WRITTEN |
| Monday, December 30, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, December 30, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 30, 2019 | ASSIGNED TO LIE |
| Monday, December 9, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, June 24, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, June 24, 2019 | NON-FINAL ACTION E-MAILED |
| Monday, June 24, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, June 14, 2019 | ASSIGNED TO EXAMINER |
| Monday, April 22, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, April 8, 2019 | NEW APPLICATION ENTERED |